President Museveni has congratulated Dr. Misaki Wayengera, a Researcher at Makerere University College of Health Sciences, for his efforts in developing a rapid test kit to diagnose the deadly Ebola and Marburg viruses. Dr Wayengera is an EDCTP Career Development Fellow (TMA2016CDF1545).
“I want to congratulate our scientists because they are really waking up and producing a lot of products. The Government will fund you. It is the issue of prioritization and putting the money in the right place,” he said. The President was on Tuesday speaking during a meeting at State House, Entebbe to recognize Dr. Misaki Wayengera who recently won the World Health Organization (WHO) high innovation challenge in Product Development Category that took place at the WHO Africa Regional Headquarters in Congo (Brazzaville).
Dr Wayengera’s invention also known as Pan-Filovirus Rapid Diagnostic Test, uses a paper-strip test, like the one used in testing for pregnancy. This, however, will be used in detecting Ebola, Marburg and other hemorrhagic fevers. Africa has had several hemorrhagic fever outbreaks especially Ebola Virus Disease (EVD) with the latest and ongoing outbreak currently in the Democratic Republic of Congo that borders Uganda to the West. Rapid diagnosis is important in informing key decisions especially interventions and measures to take in the event of a disease outbreak. If approved by health authorities including the World Health Organization (WHO) and partners, Dr Wayengera’s Pan-Filovirus Rapid Diagnostic Test will go a long way in improving rapid tests and turnaround time for results during disease outbreaks. President Museveni said that the Government of Uganda will support the efforts of the researchers by establishing a manufacturing facility that will enable them to put all the products together. He commended Dr. Wayengera and his team on the achievements realized adding that the research can bring in a host of benefits to society because the products form the core that addresses many human challenges such as hemorrhage fevers and HIV afflictions that immensely affect the world. The President observed that Uganda has, on several occasions, been attacked by epidemics, including Ebola and Marburg, resulting in the deaths of trained preventive workers and wananchi. State Minister for Health, Hon. Sarah Ochieng Opendi, saluted Dr. Wayengera and his team for the innovation saying their efforts will go a long way in easing the diagnosis of viral hemorrhage fevers such as Ebola and Marburg. Dr. Wayengera, on his part, thanked President Museveni for recognizing their efforts and his support.
The Stop
TB Partnership Working Group on New TB Vaccines (WGNV) and the National
Institute for Allergy and Infectious Diseases (NIAID)are
co-hosting a workshop on the topic of Recognition and Control of Mtb
Infected Cells: From Basics to the Clinic. This workshop is intended to address
the need for correlates and to identify platforms that measure recognition or
control of the infected cell - especially in humans - as identified in the EDCTP/AIGHD Global Roadmap for
Research and Development of New TB Vaccines and the Strategic Framework for
New TB Vaccines in the Stop TB Partnership Global Plan to End TB 2023 - 2030.
The overall goals of this workshop
are to:
The workshop format will be largely
discussion-based. Each session will have three short presentations that will
provide a high-level overview of key topics within the session theme, followed
by a discussion between the session chairs, speakers, and participants.
Click here
to view the programme and
speakers.
This workshop is free of charge and
open to any participants interested in this topic.
The International Society for Infectious Diseases (ISID) and the Swiss
Society for Infectious Diseases (SSI) are inviting applications for their joint
Infectious Diseases Research Fellowship Program. The purpose of this programme
is to support infectious disease physicians and scientists from under-resourced
countries through multidisciplinary clinical and laboratory training at a
select biomedical institution in Zurich, Switzerland. The one-year SSI/ISID
Fellowship programme is open to applicants who are 40 years or younger,
citizens and permanent residents of under-resourced countries or Eastern
Europe. The deadline for applications is 16 June 2023.
More information: https://na.eventscloud.com/eSites/748378/Homepage
The MRCT Center and Medable convened a multi-stakeholder task force to address ethical and regulatory opportunities and challenges related to Decentralized Clinical Trials (DCTs). Join them on June 20, from 10 - 11 AM ET, for a joint webinar entitled, "Ethical Review of Decentralized Clinical Trials (DCTs): Tools, Resources & Best Practices."
During the webinar, Barbara Bierer (MRCT Center), Pam Tenaerts
(Medable) and Leanne Madre (Medable) will present a framework, recommendations,
and tools organized around 3 DCT domains: People, Remote Data Collection, and
Data Oversight. Best practices for the ethical review, approval, and conduct of
DCTs will be provided.
Clinical trial stakeholders (IRB/ECs,
HRPP, sites, sponsors, investigators, and others) to register for the webinar here